We describe here the design, synthesis, molecular modeling, and biological evaluation of a series of small molecule, nonpeptide inhibitors of SARS-CoV PLpro. Our initial lead compound was identified via high-throughput screening of a diverse chemical library. We subsequently carried out structure-activity relationship studies and optimized the lead structure to potent inhibitors that have shown antiviral activity against SARS-CoV infected Vero E6 cells. Upon the basis of the X-ray crystal structure of inhibitor 24-bound to SARS-CoV PLpro, a drug design template was created. Our structure-based modification led to the design of a more potent inhibitor, 2 (enzyme IC 50 = 0.46 μM; antiviral EC 50 =6 μM). Interestingly, its methylamine derivative, 49, displayed good enzyme inhibitory potency (IC 50 = 1.3 μM) and the most potent SARS antiviral activity (EC 50 =5.2 μM) in the series. We have carried out computational docking studies and generated a predictive 3D-QSAR model for SARS-CoV PLpro inhibitors.
Introduction
Severe acute respiratory syndrome (SARS), a contagious and fatal respiratory illness, was first reported in Guangdong province, China, in November 2002. 1 It rapidly spread to other Asian countries, North America, and Europe, creating panic to both the public and the World Health Organization (WHO a ). The emergence of SARS affected more than 8000 individuals and caused 774 deaths within a few months. 6 Quite remarkably, the spread of SARS-CoV was effectively halted within months after the initial outbreaks through public health measures. Through a concerted effort monitored by the WHO, scientists determined that SARS is caused by a novel coronavirus, SARS-CoV. 2,3,3b The more recent isolation of strains from zoonotic origins thought to be the reservoir for SARS-CoV emphasizes the possibility of a reemergence. 4, 5 It is quite alarming just how rapidly a contagious illness can spread in the more mobile and highly interconnected world of the 21st century. While there are no new reports of SARS cases, there is no guarantee that this outbreak will not strike again. Therefore, development of antivirals effective against SARS-CoV is important for future outbreaks.
The identification of biochemical events critical to the coronaviral lifecycle has provided a number of significant targets for halting viral replication. One of the early and essential processes is the cleavage of a multidomain, viral polyprotein into 16 individual components termed nonstructural proteins, or nsps. These proteins assemble into complexes to execute viral RNA synthesis. 7 Two cysteine proteases, a papain-like protease (PLpro) and a 3C-like protease (3CLpro), reside within the polyprotein. They catalyze their own release and that of the other nsps from the polyprotein and initiate virus-mediated RNA replication. Since 2003, numerous biochemical, structural, and inhibitor development studies have been directed at the 3CLpro enzyme, 8 which cleaves 11 sites within the polyprotein. Recently, we reported potent inhibitors of 3CLpro that have shown antiviral activity against SARS-CoV. 9 Recent structural and functional studies directed at PLpro have suggested potential roles for this protease beyond viral peptide cleavage, including deubiquitination, deISGylation, and involvement in virus evasion of the innate immune response. 10, 11 Furthermore, studies have shown that the homologous enzyme, PLP2, from the human coronavirus 229E, is essential for 229E viral replication. 12 Therefore, PLpro has emerged as a significant drug development target. Our screening of a structurally diverse library of 50080 compounds led to the discovery of a noncovalent lead inhibitor 1 (7724772, Figure 1) , with an IC 50 value of 20 μM as a racemic mixture. 13 Subsequent SAR studies and lead optimization provided potent inhibitor 24 (IC 50 =600 nM), which also inhibits SARS-CoV viral replication in Vero cells with an EC 50 value of 15 μM. 13 In these studies, we also reported the X-ray crystal structure of SARS-CoV PLpro bound to inhibitor 24, which revealed important molecular insight into the ligand-binding site interactions. We now describe the full details of our significantly extended studies that include the design, synthesis, molecular modeling, and biological evaluation of a series of inhibitors of SARS-CoV PLpro.
Chemistry
As shown in Scheme 1, coupling of (R)-(þ)-1-(2-naphthyl)ethylamine or (R)-(þ)-1-(1-naphthyl)ethylamine with benzoic acid derivatives utilizing N-(3-dimethylaminopropyl)-N 0 -ethylcarbodiimide hydrochloride (EDCI), 1-hydroxybenzotriazole hydrate (HOBT) in the presence of diisopropylethylamine in CH 2 Cl 2 at 23°C gave the corresponding inhibitor in excellent yield. Inhibitors 8 and 9 were synthesized by general methods with N-Boc protected benzoic acid derivative followed by deprotection of the Boc group as shown in Scheme 2. Protection of p-aminobenzoic acid 6 with di-t-butyl dicarbonate in the presence of triethylamine in a mixture (2:1) of dioxane and water at 23°C for 16 h gave the corresponding t-Bu carbamate 7.
14 A coupling reaction utilizing EDCI and HOBt provided inhibitor 8. Removal of the Boc group with trifluoroacetic acid in CH 2 Cl 2 at 23°C for 2 h afforded inhibitor 9.
Inhibitors 14 and 17 were racemic compounds (Scheme 3). A Friedel-Crafts reaction of naphthalene 10 with propionyl chloride 11 in the presence of aluminum chloride in 1,2-dichloroethane at 35°C for 4 h gave ethyl naphthyl ketone 12.
15 Reductive amination 16 with ammonium acetate and sodium cyanoborohydride in methanol at 23°C for 24 h generated amine 13. Coupling of this amine with o-toluic acid provided inhibitor 14. Reductive amination of naphthyl phenyl ketone 15 by using similar conditions as the amine 13 gave amine 16. Coupling of 16 with o-toluic acid furnished inhibitor 17.
Inhibitor 21 with N-methyl amide was prepared as shown in Scheme 4. Protection of (R)-(þ)-1-(1-naphthyl)-ethylamine 18 with methyl chloroformate in the presence of potassium carbonate in a mixture (1:1) of dioxane and water at 0°C for 1 h afforded carbamate 19. Reduction of 19 with lithium aluminum hydride in THF at reflux for 1 h gave methylamine 20. A coupling reaction utilizing general methods provided inhibitor 21. Inhibitor 23 was prepared by coupling of optically active amine 18 with acid 7 as shown. Inhibitors 24 and 25 containing 2-methyl-5-amino derivatives were synthesized as outlined in Scheme 5. Reduction of the nitro group in 5i by catalytic hydrogenation in the presence of 5% Pd-C in a mixture (1:1) of ethyl acetate and methanol at 23°C for 15 h provided inhibitor 24. Acetylation of 24 with acetic anhydride and triethylamine in CH 2 Cl 2 at 23°C for 18 h generated inhibitor 25. The synthesis of inhibitor 29 with a gem-dimethyl group in the R-naphthyl side chain was carried out by dimethylation of 1-cyanonaphthalene 26 with methyl lithium in the presence of cerium(III) chloride in tetrahydrofuran at 23°C for 2 h to provide amine 27. 17 A coupling reaction using the general method described above provided 28, and hydrogenation in the presence of 5% Pd-C in a mixture (1:1) ethyl acetate and methanol at 23°C for 15 h provided inhibitor 29.
The synthesis of 32 with 2-methyl-5-iodide and 33 with 2-methyl-5-cyanide substituents on the benzamide moiety is outlined in Scheme 6. Iodination of o-toluic acid 30 with sodium periodate and potassium iodide in concentrated sulfuric acid at 25-30°C for 2 h afforded iodide 31. 18 The coupling reaction following the general method provided inhibitor 32, and cyanation with copper cyanide and sodium cyanide in DMF at 130°C for 16 h furnished inhibitor 33. Inhibitor 40 was synthesized by esterification of 34 in the presence of thionyl chloride in methanol at reflux for 4 h to provide ester 35. Bromination of 35 with N-bromosuccinimide and benzoyl peroxide in carbon tetrachloride at reflux for 24 h generated bromide 36. 19 Reaction of 36 with sodium hydride and sodium methoxide in methanol at 50°C for 4 h provided 37. 20 Hydrolysis of 37 with lithium hydroxide monohydrate in a mixture (5:1) of tetrahydrofuran and water at 23°C for 16 h afforded acid 38. Coupling reaction with the general method gave 39 and hydrogenation in the presence of 5% Pd-C in ethyl acetate at 23°C for 10 h provided inhibitor 40.
Inhibitors 47, 49, and 2 have been synthesized as shown in Scheme 7. Reduction of nitro group in 35 by catalytic hydrogenation in the presence of 5% Pd-C in ethyl acetate at 23°C for 15 h provided amine 41. Reaction of 41 with sodium nitrite, copper cyanide, and sodium cyanide in acidic condition at 23°C for 3 h afforded corresponding benzonitrile 42. 21 Reduction and subsequent N-Boc protection with di-t-butyl dicarbonate and sodium borohydride in the presence of nickel(II) chloride hexahydrate in methanol at 23°C for 2 h provided N-Boc-benzylamine 43.
22
N-Methylation with methyl iodide and potassium bis-(trimethylsilyl)amide in tetrahydrofuran at 23°C for 16 h afforded methylamine 44. Hydrolysis of 43 with lithium hydroxide monohydrate in a mixture (9:1) of tetrahydrofuran and water at 23°C for 16 h generated acid 45. Coupling reaction of 45 with amine 18 using conditions described above provided inhibitor 47. Removal of Boc group with trifluoroacetic acid in dichloromethane at 23°C for 2 h gave inhibitor 2. Inhibitor 49 was prepared from benzylamine 44. Ester hydrolysis, coupling of the resulting acid with amine 18, and subsequent removal of Boc-group as described for 2 afforded inhibitor 49.
Results and Discussion
As described previously, screening of a library of 50080 diverse compounds identified 1 as an inhibitor of PLpro activity. 13 Because 1 is a racemic mix, we synthesized the corresponding chiral compounds to evaluate the stereospecific recognition of these compounds by PLpro. Compound 1 with the R-configuration, was found to be twice as potent as the racemic compound 1 (R-configuration compound, IC 50 = 8.7 μM; racemic compound 1, IC 50 =20.1 μM). We therefore selected R-configuration compound for further optimization as the lead compound.
As shown in Table 1 , we modified the substituent on the benzamide ring with methyl and methoxy groups. Compounds 5a-5e turned out to be less potent than the lead compound. Thus, a methyl group at the ortho position in lead compound displayed the most potent activity (IC 50 =8.7 μM). A methoxy group at the ortho position resulted in a 10-fold reduction in potency compared to the lead compound. A methoxy group in the meta position (compound 5f, IC 50 = 13.5 μM) is the most potent analogue among the methoxy substituted derivatives. We next attempted further modification of the substituent on the benzamide as well as on the naphthyl rings, and the results are summarized in Table 2 . As shown, a 2,6-dimethyl derivative, 5f, led to an increase in the IC 50 value compared to lead compound (compound 5f, IC 50 = 12.1 μM). Bulky substituents at the ortho and para positions of the benzamide ring and R-naphthyl position also resulted in increased IC 50 values.
In an attempt to further improve the potency of PLpro inhibitors, we then examined 1-naphthalene derivatives and also explored polar functionalities on the benzamide ring based upon modeling studies. The results are shown in Table 3 . Compound 5h, with a R-1-naphthylethylamide derivative, shows improvement in potency compared to the lead compound (compound 5h, IC 50 =2.3 μM). The importance of an amide NH is demonstrated as the N-methyl derivative has significantly attenuated potency (compound 21, IC 50 = 22.6 μM; compound 5h, IC 50 =2.3 μM). 5-Amino group resulted in an even more potent inhibitor 24 with an IC 50 value of 0.56 μM. However, incorporation of a polar acetamide derivative afforded a less potent derivative (compound 25, IC 50 = 2.6 μM).
To obtain molecular insights into the ligand-binding site interactions responsible for the inhibitory potency of compound 24, the X-ray structure of PLpro complexed with 24 was determined previously to 2.5 Å resolution. 13, 23 Comparison of the apoenzyme SARS-CoV PLpro structure to the inhibitor 24-complexed structure reveals significant conformational differences between these structures. 23 Upon the basis of this molecular insight, we further modified the substituents on the benzamide ring. Particularly interesting is the fact that the amine group in 24 is positioned at the opening of the cleft where it appears to come within hydrogenbonding distance to the hydroxyl of Tyr269. Furthermore, there are a number of water molecules present (see Figure 2 ) that occupy the pocket accommodating the (R)-methyl substituent of 24. This suggested the potential for extending the methyl branch further into the pocket through the addition of polar substituents. As shown in Table 4 , we incorporated a dimethyl group in place of the (R)-methyl substituent, however, the corresponding inhibitor showed a reduction in potency for SARS PLpro (compound 29, IC 50 = 11.1 μM). Upon the basis of the X-ray structure, we then incorporated 5-methylamine substituents on the benzamide ring. The resulting compound 2 showed a slight improvement in inhibitory potency (compound 2, IC 50 =0.46 μM) and antiviral activity (EC 50 = 6 μM) as shown in Table 5 . The addition of a methyl group to the amine group of 2 provided compound 49, which showed slightly decreased enzyme activity (IC 50 = 1.3 μM) but significantly improved antiviral potency (EC 50 = 5.2 μM). These results illustrate the importance of testing compounds not only for their ability to inhibit the purified protein but also to assess their effects on cell viability and inhibition of viral replication in a cell-based assay.
To obtain molecular insights into the active site interactions leading to improved inhibitory potency, we created an energyminimized model of 2 in the 24-inhibited SARS-CoV PLpro active site ( Figure 2B ). The model reveals that the 5-methylamine substituent of inhibitor 2 may be involved in hydrogen The three conserved water molecules are marked; two of them are buried deep in the pocket (P5), whereas the third one lies in a groove between residues Lys158 and Glu168. The position of these water molecules is integral to structure-based inhibitor design efforts. The crystal structure conformation of compound 24 is shown in cyan, whereas the docked conformation of compound 2 in the presence of water molecules (red dots) is shown in green. bonding with the side chain of residues Gln270 and Tyr269. Similar to the crystal structure conformation of compound 24, compound 2 appears to be anchored in the site by two effective hydrogen bonds made between the carboxamide group and residues Asp165 and Gln 270. The three conserved water molecules found in both the complex crystal structure of compound 24-bound protein and the crystal structure of the apo enzyme are retained for modeling studies and are shown as red dots in the P5 binding pocket (see Figure 2B ). In docking studies, these water molecules are necessary for obtaining the crystal-bound orientation of these compounds, which positions the naphthyl ring of the inhibitor to be flipped upward holding the loop (shown in cyan, Figure 2A ). In the absence of these three waters, the naphthyl ring tends to occupy the P5 pocket, shown in green, Figure 2A .
To better quantitate and understand the contributions of the inhibitor substituents to the inhibitory potency, we also conducted an extensive quantitative structural activity relationship (QSAR) analysis. QSAR studies are often employed as a standard method to determine valuable information for designing novel and potent inhibitors. An alternative approach to labor-intensive chemical synthesis is to develop a theory that quantitatively relates variations in biological activity to changes in molecular descriptors for each compound. The goal of our computational study was to develop a robust QSAR model that can predict and differentiate inhibition values of this series of inhibitors against SARS-CoV PLpro. Partial least-squares (PLS) methodology was used for the 3D-QSAR analyses. The CoMSIA descriptors were used as independent variables, and percent inhibition values at 100 μM were used as dependent variables in PLS regression analyses to derive the models. The predictive value of the models were evaluated by leave-one-out (LOO) cross-validation. To assist ligand-based structure design efforts, we used docking in conjunction with 3D-QSAR (CoMSIA) to investigate the SAR of 46 inhibitors with considerable structural diversity and a wide range of bioactivity against the SARSCoV PLpro.
The crystal structures of the apo protein (PDB id: 2fe8) 11 and the inhibitor 24-bound form (PDB id: 3e9s) 13 were carefully studied, and it was determined that three water molecules are conserved in the active sites of both the structures; two are buried deep in the P5 pocket and one between residues Lys158 and Glu168. Apart from these three conserved water molecules, two additional water molecules are located at the ridge by the P5 pocket in the inhibitor-bound form of the protein.
As previously mentioned, by conducting extensive analyses both with and without water molecules bound to the structures, we determined that retaining the three conserved water molecules made a substantial difference in replicating the crystal structure binding geometry of compound 24 in docking studies. When docking was performed in the absence of water molecules in the P5 pocket, the study suggested that the naphthyl rings prefer to flip downward and probably find lower energy conformations in this pocket as shown in Figure 2A . In the inhibitor 24-bound crystal structure, two of the conserved water molecules hinder placement of the naphthyl rings in the P5 pocket and thereby flip the rings upward. This position of the naphthyl rings fits nicely in the hydrophobic pocket and forms favorable interactions with the flexible loop residues. The five water molecules mentioned above are clearly shown in Figure 2B and were retained for the docking procedure prior to CoMSIA 24 model generation. In Figure 2B , the superimposition of the naphthyl rings of modeled compound 2 (green) and X-ray structure bound orientation of compound 24 (cyan) is clearly shown as obtained in the presence of the conserved water molecules.
Using the binding conformation of inhibitor 24 from the crystal structure as a template, 45 other inhibitors were docked. The docked geometry of these 45 inhibitors aligned very well with the binding geometry of compound 24 in the crystal structure. A predictive 3D-QSAR model was derived from the alignment of the docked conformations of the inhibitors as extracted directly from the 3D coordinates of the docked complexes. A successful CoMSIA model was built with a cross-validated q 2 of 0.678 and bootstrap R 2 of 0.984. It is imperative to mention here that without the inclusion of at least the three conserved water molecules, the docking geometry of the inhibitors does not align with the crystal structure (as shown in Figure 2A ). In the absence of these water molecules, the wrong ligand conformation is generated where the naphthyl ring is flipped into the P5 pocket, consequently resulting in an SAR with no correlation.
The CoMSIA model at six components gave a crossvalidated q 2 of 0.678, r 2 of 0.984, F of 302.2, and a mean standard error estimate of 4.72. The high r 2 of 0.984 illustrates that the physicochemical descriptors chosen were appropriate to describe the binding interactions mode of the various inhibitors with the PLpro active site. The plot shown in Figure 3 shows the correlation between the experimental percent inhibition values of 41 compounds and the inhibition percentages predicted by the CoMSIA model. The contour maps generated, shown in Figures 4A-C, were mapped back to the topology of the active site to reveal that electrostatic, hydrophobic, and steric fields were in accordance with the distribution of the binding site residues. These contour maps should prove to be helpful in determining the incorporation of functional groups for the inhibitors that can extensively interact with specific binding pocket residues. We conclude that this robust 3D-QSAR model built using CoMSIA can be used as a reliable guide for future structure-based drug design efforts.
Conclusion
In summary, a series of novel inhibitors of SARS-CoV PLpro has been designed, synthesized, and evaluated in enzyme inhibitory and antiviral assays. Initial lead compound 1 was discovered via high-throughput screening. This racemic compound has shown enzyme IC 50 value of 20 μM. The stereochemical preference for the R-isomer was established through synthesis and evaluation of optically pure inhibitors, and kinetic studies showed that the optically pure lead inhibitor is a reversible inhibitor of SARS-CoV-PLpro enzyme. In the absence of any structural information, initially our structure-activity relationship studies and systematic modification guided by molecular modeling studies provided potent inhibitor 24. This inhibitor displayed enzyme inhibitory activity of 560 nM and antiviral EC 50 value of 14.5 μM in SARS-CoV infected Vero E6 cells. A protein-ligand X-ray structure of 24-bound SARS-CoV PLpro provided detailed molecular interaction in the active site of PLpro enzyme. Upon the basis of the X-ray structural information, our structure-based design led to identification of potent inhibitors 2 and 49. Inhibitor 2 has shown potent enzyme inhibitory activity of 460 nM and antiviral EC 50 value of 6 μM against SARS. Interestingly, the corresponding methylamine derivative 49 (enzyme IC 50 =1.3 μM) has shown most potent antiviral activity against SARS (EC 50 =5.2 μM). To obtain molecular insight into the binding properties of 2 and its derivative, we have created an active model based upon the X-ray structure of 24-bound SARS PLpro. It appears that the methylamine functionality is within proximity to hydrogen bond with the side chain residues of Gln270 and Tyr269. We have also carried out computational docking studies and generated a predictive 3D-QSAR model for SARS-CoV PLpro. Further design of reversible SARS-CoV PLpro inhibitors is currently underway in our laboratory.
Experimental Section
Chemistry.
H NMR and
13 C NMR spectra were recorded on Varian Oxford 300 and Bruker Avance 400 spectrometers. Optical rotations were recorded on Perkin-Elmer 341 polarimeter. Anhydrous solvent was obtained as follows: dichloromethane by distillation from CaH 2 , THF by distillation from Na and benzophenone. All other solvents were reagent grade. Column chromatography was performed with Whatman 240-400 mesh silica gel under low pressure of 3-5 psi. TLC was carried out with E. Merck silica gel 60-F-254 plates. Purity of all test compounds was determined by HRMS and HPLC analysis on an Agilent 1100 unit in two different solvent systems. All test compounds showed g95% purity.
General Procedure for Coupling Reaction of Naphthylethylamine and Benzoic Acid Derivative. þ 334.1323. 4-N-tert-Butoxycarbonylaminobenzoic Acid (7). To a solution of 4-aminobenzoic acid 6 (520 mg, 3.8 mmol) in dioxane/H 2 O (2:1) (13 mL) was added triethylamine (0.79 mL, 5.7 mmol) and Boc 2 O (1.31 mL, 5.7 mmol) at 23°C and it was allowed to stir for 48 h at same temperature. The solvent was removed under reduced pressure, and 3 M HCl (5 mL) was added dropwise to the residue at 0°C. A precipitate was obtained, collected, washed with water, and dried to give corresponding acid 7 (836 mg, 93%) as slightly yellow solid, R f =0.78 (CH 2 Cl 2 :Me-OH=9:1). 1 
4-Amino-N-[(R)-1-(2-naphthyl)ethyl]benzamide (9)
. To a solution of Boc 8 (60 mg, 0.15 mmol) in CH 2 Cl 2 (4 mL) was added dropwise trifluoroacetic acid (0.6 mL) at 23°C and it was allowed to stir for 2 h at same temperature. The reaction was concentrated under reduced pressure, and the residue was treated with saturated NaHCO 3 solution. The mixture was extracted with CH 2 Cl 2 . The organic layers were dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 9 (44 mg, 99%) as a white solid, R f =0.60 (CH 2 þ 290.1424. 1-(2-Naphthyl)propanone (12) . To a solution of propionyl chloride 11 (5.1 g, 55 mmol) and aluminum chloride (7.7 g, 58 mmol) in 1,2-dichloroethane (16 mL) was added dropwise a solution of naphthalene 10 (7.9 g, 62 mmol) in 1,2-dichloroethane (16 mL) over 3 h at 35°C and it was allowed to stir for 1 h. The reaction was added 3 M HCl solution at 0°C and then separated a white solid. The filtrate was washed with water. The organic layer was dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 12 (9.9 g, 98%) as a colorless oil, R f = 0.56 (hexane:EtOAc = 9:1). þ 303.1624. 1-(2-Naphthyl)benzylamine (16) . To a solution of naphthylphenylketone 15 (600 mg, 2.6 mmol) in MeOH (15 mL) was added ammonium acetate (2 g, 25.9 mmol) and NaBH 3 CN (120 mg, 1.9 mmol) at 23°C and it was allowed to stir for 24 h. Conc HCl was added until pH <2, and the solvent was removed under reduced pressure. The residue was taken up in water (4 mL To a solution of (R)-(þ)-1-(2-naphthyl)ethylamine 18 (200 þ96.8 (c= 1, CHCl 3 ) . 1 H NMR (300 MHz, CDCl 3 ): δ 7.82-7.74 (m, 4H), 7.50-7.40 (m, 3H), 5.14 (bm, 1H), 5.00 (bm, 1H), 3.66 (s, 3H), 1.54 (d, 3H, J = 6.9 Hz). 13 (20) . To a suspension of lithium aluminum hydride (93 mg, 2.4 mmol) in THF (6 mL) was added dropwise a solution of carbamate 19 (268 mg, 1.2 mmol) in THF (1 mL) at 0°C under argon atmosphere and it was allowed to stir for 1 h at reflux temperature. The reaction was quenched with 1 M NaOH solution at 0°C and the mixture was filtered through celite pad. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give amine 20 (186 mg, 86%) as a colorless oil, R f = 0.21 (CH 2 To a stirred solution of nitro 5m (37 mg, 0.11 mmol) in EtOAc/MeOH (1:1) (3 mL) was added 5% Pd-C (4 mg) and it was allowed to stir for 15 h at 23°C under H 2 atmosphere. The reaction was filtered through a celite pad and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 24 (27 mg, 80%) as a white solid, R f =0. 143.9, 138.0, 136.9, 133.8, 131.7, 131.1, 128.7, 128.3, 127.2,  126.5, 125.8, 125.1, 123.5, 122.5, 116.6, 113.3, 44.7, 20 .5, 18.6. (25) . To a stirred solution of amine 24 (14 mg, 0.05 mmol) in CH 2 Cl 2 (0.5 mL) was added dropwise triethylamine (9.6 μL, 0.07 mmol) and acetic anhydride (5.2 μL, 0.06 mmol) at 0°C and it was allowed to stir for 18 h at 23°C. The reaction was quenched with saturated NH 4 Cl solution and extracted with CH 2 Cl 2 . The organic layers were dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 25 (5.4 mg, 34%) as a white solid, R f =0.60 (CH 2 Cl 2 :MeOH=9:1). 1 þ 346.1682. 1-Methyl-1-(1-naphthyl)ethylamine (27). CeCl 3 3 7H 2 O (3.77 g, 10.1 mmol) was dried while stirring at 160°C under reduced pressure for 3 h. Argon was added slowly, and the flash was cooled in an ice bath. THF (20 mL) was added and the suspension was stirred at 23°C for 2 h. Methyl lithium ( 1.5 M)in THF (6.7 mL, 10.1 mmol) was added below -50°C. The mixture was stirred for 30 min at -78°C and a solution of 1-cyanonaphthalene 26 (500 mg, 3.3 mmol) in THF (2 mL) was added. Stirring at 23°C was continued for 2 h. Conc NH 4 OH (6.5 mL) was added at -78°C, and the mixture was warmed to 23°C and filtered with a celite pad. The solid was washed with CH 2 Cl 2 . The filtrate was extracted with CH 2 Cl 2 and the organic layers were dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was taken up in toluene (10 mL) and stirred with 3% H 3 PO 4 (10 mL) for 15 min. The toluene layer was extracted with water (Â2), and the combined water layers were washed with toluene and made basic with conc NH 4 þ 314.1424. 2-Methyl-5-nitrobenzoic Acid Methyl Ester (35). To a stirring MeOH (4 mL) in a round-bottom flask was added dropwise thionyl chloride (0.24 mL, 3.3 mmol) at 0°C. The mixture was added 2-methyl-5-nitrobenzoic acid 34 (300 mg, 1.7 mmol) at 0°C and it was allowed to stir for 4 h at reflux temperature. The reaction was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give corresponding compound 35 (320 mg, 99%) as a colorless oil, R f = 0.85 (hexane:EtOAc = 1:1). 2-Bromomethyl-5-nitrobenzoic Acid Methyl Ester (36). Compound 35 (100 mg, 0.53 mmol) was dissolved in CCl 4 (4 mL), followed by addition of NBS (100 mg, 0.58 mmol) and a catalytic amount of benzoyl peroxide. The mixture was stirred at reflux for 24 h. Another portion, of dibenzoyl peroxide (40 mg, 0.23 mmol) was added and then the mixture was stirred and heated at reflux for another 10 h. The mixture was allowed to cool to 23°C and was filtered. The filtrate was washed with NaHCO 3 , dried over Na 2 SO 4 , and the solvent evaporated in vacuo. The residue was purified by silica gel column chromatography to afford compound 36 in 89% yield. 2-Methoxymethyl-5-nitrobenzoic Acid Methyl Ester (37). NaH (44 mg, 1.1 mmol) was added to a round-bottomed flask containing methanol (2 mL) at 0°C. The sodium methoxide solution was added to a cold solution of compound 36 (60 mg, 0.22 mmol) in methanol (2 mL) at 0°C. The resulting solution was stirred at 50°C for 4 h. After this time, NH 4 Cl solution was poured into reaction mixture at 0°C, and the mixture was extracted with AcOEt and dried over anhydrous Na 2 SO 4 . The solvent was evaporated under reduced pressure and purification by silica gel flash column chromatography to afford corresponding compound 37 in 72% yield. 1 2-Methoxymethyl-5-nitrobenzoic Acid (38). To a stirring solution of compound 37 (36 mg, 0.75 mmol) in THF/H 2 O mixture (5 mL:1 mL) at 0°C was added solid LiOH 3 H 2 O (120 mg, 5 mmol), and the resulting solution was stirred at 23°C for 1.5 h. After this period, the reaction mixture was evaporated until 1 mL, and the mixture was extracted with toluene to remove organic impurities. The aqueous layer was cooled to 0°C, acidified with 25% aqueous citric acid until pH 3-4, extracted with AcOEt, and dried over anhydrous Na 2 SO 4 . The solvent was evaporated and purification by silica gel flash column chromatography to furnish compound 37 in 90% yield. þ 334.1679. 5-Amino-2-methylbenzoic Acid Methyl Ester (41). To a solution of nitro 35 (635 mg, 3.3 mmol) in EtOAc (10 mL) was added 10% Pd-C (30 mg) and it was allowed to stir for 16 h at 23°C under H 2 atmosphere. The reaction was filtered through a celite pad, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to furnish compound 41 (536 mg, >99%) as a colorless oil, R f = 0.57 (hexane:EtOAc=1:1). 82 (s, 3H), 3.64 (s, 2H), 2.43 (s, 3H) . 13 C NMR (100 MHz, CDCl 3 ): δ 168.1, 144.1, 132.3, 129.8, 129.5, 118.8 þ 165.0787. 2-Methyl-5-cyanobenzoic Acid Methyl Ester (42). CuCN (228 mg, 2.5 mmol) was suspended in distilled water (2 mL). NaCN (353 mg, 7.2 mmol) was added with vigorous stirring, and the internal temperature was kept below 40°C until all the CuCN went into solution. A suspension of amine 41 (350 mg, 2.1 mmol) in water (4 mL) and conc HCl (0.7 mL) was stirred and cooled in an ice bath. When the temperature reach 5°C, a solution of NaNO 2 (190 mg, 2.8 mmol) in water (0.6 mL) was added dropwise at 5°C. When all the NaNO 2 was added, the solution was added dropwise the NaCN/CuCN solution at 0°C. A few drops of methanol were added to keep the foaming under control. Stirring was continued for 3 h at 23°C. The suspension was extracted with EtOAc, and the organic layers were dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 42 (115 mg, 31%) as a colorless oil, R f = 0.63 (hexane:EtOAc=1:1). 5-N-tert-Butoxycarbonylmethylamino-2-methylbenzoic Acid Methyl Ester (43). To a solution of nitrile 42 (40 mg, 0.23 mmol) in MeOH (1.5 mL) was added Boc 2 O (0.1 mL, 0.46 mmol) and NiCl 2 3 6H 2 O (5.4 mg, 0.022 mmol) at 0°C. NaBH 4 (61 mg, 1.6 mmol) was then added in small portions over 15 min. The reaction was allowed to stir for 2 h at 23°C. At this point, diethylenetriamine (25 μL, 0.23 mmol) was added. The mixture was allowed to stir for 15 min. The solvent was removed, and the residue was dissolved with EtOAc. The organic layer was washed with saturated NaHCO 3 solution and dried over Na 2 SO 4 . The solvent was removed under reduced pressure to give a residue, which was purified by silica gel column chromatography to furnish compound 43 (54 mg, 85%) as a colorless oil, R f = 0.49 (hexane:EtOAc = 3:1). þ 278.1398. 5-(N,N-tert-Butoxycarbonylmethyl)methylamino-2-methylbenzoic Acid Methyl Ester (44). To a solution of N-Boc amine 43 (60 mg, 0.21 mmol) in THF (3 mL) was added dropwise 0.5 M KHMDS in toluene (0.64 mL, 0.32 mmol) at 0°C under argon atmosphere and it was allowed to stir for 30 min at 0°C. The mixture was added dropwise MeI (21 μL, 0.34 mmol) at 0°C and it was allowed to stir for 16 h at 23°C. The reaction was quenched with saturated NH 4 Cl solution and extracted with EtOAc. The organic layers were dried over Na 2 SO 4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give compound 44 (52 mg, 83%) as a colorless oil, R f = 0.60 (hexane:EtOAc = 3:1). 1 5-N-tert-Butoxycarbonylmethylamino-2-methylbenzoic Acid (45). To a solution of ester 43 (54 mg, 0.19 mmol) in a mixture (9:1) of THF and water (2 mL) was added LiOH 3 H 2 O (12 mg, 0.29 mmol) at 0°C and it was allowed to stir for 16 h at 23°C. The reaction was concentrated under reduced pressure, and the residue was diluted with saturated NaHCO 3 solution. The mixture was extracted with Et 2 O, and the aqueous layer was acidified with 1 M HCl solution to pH 4. The white solid was extracted with EtOAc, and the organic layers were dried over
